• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
37 results

EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY

Docket 16/312,803, U.S. Patent Application (Dec. 21, 2018)
Art Group1635
Case TypeUtility - 514/04400A
Class514
Inventor Richard K. BESTWICK
Inventor Diane Elizabeth FRANK
Applicant Sarepta Therapeutics, Inc.
cite Cite Docket
Analyze

Non-Final Rejection

Document EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY, 16/312,803, No. 1-12-US-163128030XP1 (U.S. Pat. App. Jan. 29, 2020)
Certified copies: a)I:I All b)C] Some** c)C] None of the: 1.[:] Certified copies of the priority documents have been received.
cite Cite Document
Analyze

Search information including classification, databases and other search related notes

Document EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY, 16/312,803, No. 14-1-US-163128030XP1 (U.S. Pat. App. Jan. 29, 2020)
FRAN K et al. Art Unit CPC - Searched* Symbol * See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.
Google Scholar — "eteplirsen" 01/23/2020 Interference Search US C'aSS/CPC US Subclass/CPC Group U.S. Patent and Trademark Office Page 1 of 1 Part of Paper No.: 20200122
cite Cite Document
Analyze

List of references cited by examiner

Document EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY, 16/312,803, No. 13-1-US-163128030XP1 (U.S. Pat. App. Jan. 29, 2020)
Today: Therapeutic Strategies, volume 10, pages e149—e156.
Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) van Deutekom et al., Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy, Drug Discovery *A copy of this reference is not being furnished with this Office action.
Classifications may be US or foreign.
U.S. Patent and Trademark Office PTO-892 (Rev.
01-2001) Notice of References Cited Part of Paper No. 20200122
cite Cite Document
Analyze

List of References cited by applicant and considered by examiner

Document EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY, 16/312,803, No. 22-10-US-163128030XP1 (U.S. Pat. App. Jan. 29, 2020)
Sci., 298(4):278— 281(1989) BROWN, S.C. et al., “Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction,” Journal of Cell Science 112:209-216, 1999 CIRAK, S., et al. "Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomertreatment: an open-label, phase 2, dose-escalation study."
DORDUNOO, S. K., et al., “Preformulation Studies on Solid Dispersions Containing Triamterene or Temazepam in Polyethylene Glycols or Gelucire 44/14 for Liquid Filling of Hard Gelatin Capsules,” Drug Development and Industrial Pharmac , 17 12 , 1685-1713,1991 DUNCKLEY, M. G., l. C. Eperon, et al. "Modulation of splicing in the DMD gene by antisense oligoribonucleotides."
270(42): 24864-24870, The American Society for Biochemistry and Molecular Biology, United States (1995) LU; Q. L. and Mann; C. J., et al., "Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse," Nat Med 9(8): 1009- 14, (2003).
WU, B., et al., "Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development," PloS one, 65:e19906 (2011) Examiner Date *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Hum Mol Genet 17(24): 3909-18, Oxford Academic Press, England (2008) YOKOTA T et al., "Efficacy of Systematic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs," Annals of Neurology, 65(6):667-676, Vlfiley-Liss, United States (June 2009), Exhibit No. 1214 filed in lnterferences 106,007 and 106,008 on Feb. 17, 2015.
cite Cite Document
Analyze

List of References cited by applicant and considered by examiner

Document EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY, 16/312,803, No. 16-6-US-163128030XP1 (U.S. Pat. App. Jan. 29, 2020)
(Use as many sheets as necessary) Euivalent of Form PTO/SB/OSa 07-09) Comllete i Known First Named Inventor Diane Elizabeth FRANK 163 5 SHIN, Dana H.
KIM; Sung Kee et al. *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Euivalent of Form PTO/SB/O8a 07-09) Comllete i Known First Named Inventor Diane Elizabeth FRANK 163 5 SHIN, Dana H. —--_ Attorney Docket Number Examiner initials" Cite
(Use as many sheets as necessary) Euuivalent of Form PTO/SB/O8a 07-09) Comllete i Known First Named Inventor Diane Elizabeth FRANK 163 5 SHIN, Dana H. —--_ Attorney Docket Number
Name of Patentee or Applicant of Cited Document Pages, > Columns, Llnes, Where Relevant e evan Pfslages pr Figures Appear EP-2799548-Al WO-9402595-Al WO-9610390-Al WO-961039l-Al WO-9610392-Al WO-96l4057-Al WO-0224906-Al
cite Cite Document
Analyze

Examiner's search strategy and results

Document EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY, 16/312,803, No. 15-1-US-163128030XP1 (U.S. Pat. App. Jan. 29, 2020)
EAST Search History EAST Search History EAST Search History (Prior Art) gRefg Hits Search Query gPluralngime gDefault gDBs Operator Stamp g2020/01/22g g15:26
cite Cite Document
Analyze

Information Disclosure Statement (IDS) Form (SB08)

Document EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY, 16/312,803, No. 1-6-US-163128030TP1 (U.S. Pat. App. Jan. 22, 2020)
(Use as many sheets as necessary) Euivalent of Form PTO/SB/OSa 07-09) Comllete i Known First Named Inventor Diane Elizabeth FRANK 163 5 SHIN, Dana H.
5 Applicant is to place a check mark here if English language Translation is attached.
(Use as many sheets as necessary) Euivalent of Form PTO/SB/O8a 07-09) Comllete i Known First Named Inventor Diane Elizabeth FRANK 163 5 SHIN, Dana H.
(Use as many sheets as necessary) Euuivalent of Form PTO/SB/O8a 07-09) Comllete i Known First Named Inventor Diane Elizabeth FRANK 163 5 SHIN, Dana H. —--_ Attorney Docket Number
Name of Patentee or Applicant of Cited Document Pages, > Columns, Llnes, Where Relevant e evan Pfslages pr Figures Appear EP-2799548-Al WO-9402595-Al WO-9610390-Al WO-961039l-Al WO-9610392-Al WO-96l4057-Al WO-0224906-Al
cite Cite Document
Analyze
1 2 3 >>